PUBLISHER: IMARC | PRODUCT CODE: 1722774
PUBLISHER: IMARC | PRODUCT CODE: 1722774
The global dengue testing market size reached USD 610.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 911.7 Million by 2033, exhibiting a growth rate (CAGR) of 4.32% during 2025-2033. The market is primarily driven by the increasing dengue fever prevalence worldwide, advancements in diagnostic technologies, rising public health awareness, and government initiatives and funding in endemic regions across the globe.
Dengue, also known as breakbone fever, is a viral infection that spreads through the bite of an infected Aedes aegypti mosquito. It causes ache in the joints and muscles, high fever, abdominal pain, vomiting, difficulty in breathing, clammy and cold skin, headache, pain behind the eyes, fatigue, rashes, and mild bleeding in the nose and gums. It is diagnosed via dengue testing, which includes enzyme-linked immunosorbent assay (ELISA), RT-PCR, and dengue IgG/IgM rapid tests. Dengue testing is performed by medical professionals using a blood sample to identify the different serotypes of the dengue virus.
The growing cases of dengue on account of the rising global warming and breeding sites of mosquitos across the globe represents one of the major factors driving the market. Moreover, accurate and efficient diagnosis of dengue plays a pivotal role in clinical care. It assists in pathogenesis, clinical trials, outbreak control, academic research, vaccine development, surveillance activities, early detection of severe cases, and case confirmation and differential diagnosis with other infectious diseases. These benefits are positively influencing the demand for dengue testing around the world. Besides this, densely populated areas worldwide are more disease-prone due to low living conditions. This, along with poor sanitation and waste management techniques due to lack of public awareness, is stimulating the growth of the market. In addition, healthcare professionals are encouraging people to prevent dengue by self-protection and thermal fogging of insecticides. This, coupled with awareness campaigns organized by the government of several countries, is propelling the growth of the market. Other growth-inducing factors are rapid urbanization and technological advancements in the healthcare industry. Furthermore, key market players are extensively investing in research and development (R&D) activities to develop highly efficient and cost-effective dengue test kits.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Abnova Corporation, CerTest Biotec S.L., DiaSorin S.p.A., F. Hoffmann-La Roche AG, InBios International Inc., NovaTec Immundiagnostica GmbH, OriGene Technologies Inc., PerkinElmer Inc., Quest Diagnostics Incorporated and Thermo Fisher Scientific Inc.